OKYO Pharma Announces Director Acquires Shares

OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the ...

Prevent Blindness Declares First-Ever Keratoconus Week, March 23- 29, 2026, to Raise Awareness, Provide Educational Resources on the Eye Disease

Prevent Blindness, the nation's leading patient advocacy organization dedicated to preventing blindness and preserving sight, has declared March 23-29, 2026, as its first-ever Keratoconus Week. The ...
Easy Reader News

Thinking about a certified ophthalmologist in Cape Coral? Here is how to choose with confidence

When text on street signs starts to blur or night driving feels harder than it used to, choosing a certified ophthalmologist in Cape Coral becomes less of ...

OKYO Pharma Announces Chief Development Officer and Director Acquires Shares

OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye ...
Cyprus Mail

Spanish researchers develop low-cost artificial cornea from fish scales

Researchers at Spain's University of Granada have developed an artificial cornea made from the scales of several fish ...

Eye health for women over 50: 6 things that change after menopause

Women over 50 face increased eye health risks post-menopause due to hormonal shifts. Conditions like dry eye, cataracts, glaucoma, and age-related macular degeneration become more prevalent.
PharmiWeb

Glaukos Announces Commercial Availability of Epioxa™, a Transformative Innovation in Interventional Keratoconus Care

Epioxa Provides the Ophthalmic Community and Patients with the First and Only FDA-Approved, Incision-Free, Topical Drug Therapy for Keratoconus, a Sight-Threatening Rare DiseaseALISO VIEJO, ...

The Everyday Contact Lens Habit That Could Be Hurting Your Eye Health

Your eyes are exposed to bacteria from your hands, the environment and other factors. Normally, your tears work to flush ...

OKYO Pharma Reports New Phase 2 Data Demonstrating Meaningful Improvements in Patient-Reported Quality of Life Outcomes with Urcosimod in Neuropathic Corneal Pain

OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye ...
Kauppalehti

OKYO Pharma Announces Chairman and Founder Acquires Shares

OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye ...

Itchy eyes? Experts reveal the causes and what you can do about them

Dry eyes are also a common source of itch - the result of hormonal changes related to aging, taking certain medications, some autoimmune diseases like rheumatoid arthritis, and staring at screens ...

Technology And Centres Of Excellence Power Maxivision’s Vision For More Accessible Advanced Eye Care

Maxivision Super Speciality Eye Hospitals, technological advancement is closely integrated with clinical expertise to improve patient outcomes and expand access to quality eye care.